Alpha Cognition Inc. (ACOGF)
Alpha Cognition Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $5.72, giving a market capitalisation of $35.7M. On trailing twelve-month figures it carries a trailing P/E of -38.17, a net margin of 0.0%. Its beta of 3.29 implies it has historically moved more than the broad market.
Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for severe neurological conditions, including Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Its developmental pipeline features ALPHA-1062, an acetylcholine esterase inhibitor designed to address dementia of the Alzheimer's type and mild traumatic brain injury. The company is also advancing ALPHA-0602, a gene therapy candidate specifically for ALS. Founded in 2000, the company initially operated as Crystal Bridge Enterprises Inc. before officially changing its name to Alpha Cognition Inc. in March 2021. The corporate headquarters are located in Vancouver, Canada.
Alpha Cognition Inc. is most often compared with the following Healthcare names: